Skip to main content
Caplight Logo









Second Genome

Second Genome

Private
South San Francisco, CaliforniaHealthcare & Life Scienceshttps://secondgenome.com

Last Round

M&A

Jan 2, 2024

Total Funding Raised

$114.36M

Company Overview

Second Genome is a biotechnology company that utilizes a microbiome data platform to extract microbial genetic insights for the development of precision therapies and biomarkers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Healthcare Analytics, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

microbiome discoverydrug discoverybiomarker identificationmulti-omicstherapeutic targetsnext-generation sequencingNGSmicrobiome therapeuticsbiotech platformcomputational biologyprecision medicinegut healthdrug pipelinebioinformaticsAI in biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Second Genome Comparables

Compare Second Genome with similar companies based on industry and business-model similarity.

Second Genome comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Microbiotica
78%
Nuanced Health
78%
Cmbio
76%

Second Genome Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AJan 2, 2024
Corporate FundingApr 6, 2020
GrantSep 1, 2019
GrantJul 1, 2017
Series B ExtensionJul 13, 2016
Series B
Apr 20, 2016

Second Genome Investors

Notable investors and investment history

Second Genome investors
InvestorRounds
Roche Venture FundSeries B
Digitalis VenturesSeries B, Series B Extension
Schroder AdveqSeries B
NIH RADxGrant
Wavepoint VenturesSeed, Series A
Lifeforce CapitalSeries B
Seraph GroupSeries B, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 2, 2024

    Completed an M&A funding round.

  • Sep 1, 2019

    $967K grant received from NIH RADx.

Second Genome Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Second Genome Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Second Genome's valuation, stock price, and market status.

Firmographic Details

HeadquartersSouth San Francisco, California
Employee Range4
Year Founded2010
Last FundingJan 2, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?